These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 33879827)
1. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. Falini B; Sciabolacci S; Falini L; Brunetti L; Martelli MP Leukemia; 2021 Nov; 35(11):3113-3126. PubMed ID: 33879827 [TBL] [Abstract][Full Text] [Related]
2. How I diagnose and treat NPM1-mutated AML. Falini B; Brunetti L; Martelli MP Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486 [TBL] [Abstract][Full Text] [Related]
3. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML. Falini B; Dillon R Blood Cancer Discov; 2024 Jan; 5(1):8-20. PubMed ID: 37917833 [TBL] [Abstract][Full Text] [Related]
4. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia. Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304 [TBL] [Abstract][Full Text] [Related]
5. Minimal/Measurable Residual Disease Monitoring in Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199 [TBL] [Abstract][Full Text] [Related]
6. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114 [TBL] [Abstract][Full Text] [Related]
7. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study. Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047 [TBL] [Abstract][Full Text] [Related]
8. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266 [TBL] [Abstract][Full Text] [Related]
10. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. Tiong IS; Loo S Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902217 [TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560 [TBL] [Abstract][Full Text] [Related]
12. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
13. The Role of Nucleophosmin 1 ( Kelemen K Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054502 [TBL] [Abstract][Full Text] [Related]
14. TG-interacting factor 1 improves risk stratification in patients with NPM1-mutated acute myeloid leukemia. Tang H; Zhang N; Li H; Chen Y; Liu X; Xiao H; Deng J; Zhou K Adv Clin Exp Med; 2023 Jul; 32(7):741-751. PubMed ID: 36753372 [TBL] [Abstract][Full Text] [Related]
15. Early Prediction and Streamline of Nucleophosmin Mutation Status in Acute Myeloid Leukemia Using Cup-Like Nuclear Morphology. Jakovic L; Djordjevic V; Kraguljac Kurtovic N; Virijevic M; Mitrovic M; Trajkovic L; Vidovic A; Bogdanovic A Medicina (Kaunas); 2024 Sep; 60(9):. PubMed ID: 39336484 [No Abstract] [Full Text] [Related]
16. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275 [TBL] [Abstract][Full Text] [Related]
17. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Chan O; Al Ali N; Tashkandi H; Ellis A; Ball S; Grenet J; Hana C; Deutsch Y; Zhang L; Hussaini M; Song J; Yun S; Talati C; Kuykendall A; Padron E; Walker A; Roboz G; Desai P; Sallman D; Sweet K; Komrokji R; Lancet J Blood Adv; 2024 Mar; 8(5):1075-1083. PubMed ID: 38170740 [TBL] [Abstract][Full Text] [Related]